Results 41 to 50 of about 1,991 (194)

Metabolite‐sensitive cross‐bridge models of human atria reveal the impact of diabetes on muscle mechanoenergetics

The Journal of Physiology, EarlyView.
Abstract figure legend In this study, we used mathematical modelling to explore the effect of diabetes on muscle mechanoenergetics. Our parameterisation of cross‐bridge models using data from non‐diabetic and diabetic human atrial tissues revealed lower values for cross‐bridge stiffness, detachment rates, attachment rates and lower ATP sensitivity in ...
Julia H. Musgrave, June‐Chiew Han, Marie‐Louise Ward, Andrew J. Taberner, Kenneth Tran   +4 more
wiley   +1 more source

Translating cardiovascular ion channel and Ca2+ signalling mechanisms into therapeutic insights

The Journal of Physiology, EarlyView.
Abstract figure legend This white paper integrates mechanistic discoveries across ion channel biology, Ca2+ signalling and multiscale cardiovascular physiology to highlight new opportunities for accelerating research and guiding next‐generation therapies. Printed with permission from ®Anita Impagliazzo Medical Illustration. [Correction added on 2 March
Silvia Marchianò, Miguel Martín‐Aragón Baudel, Charlotte E. R. Smith, Gonzalo Hernandez Hernandez, Donald M. Bers, Patrick M. Boyle, Dobromir Dobrev, Shanna Hamilton, Osama F. Harraz, Na Li, Thomas A. Longden, William E. Louch, Madeline Nieves‐Cintron, Matthew A. Nystoriak, Walter Lee Murfee, Przemysław B. Radwański, Swapnil K. Sonkusare, Manuel F. Navedo, Eleonora Grandi   +18 more
wiley   +1 more source

Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study

Cardiology and Therapy
Introduction Mavacamten, a cardiac myosin inhibitor, has demonstrated positive outcomes in left ventricular outflow tract (LVOT) gradient reduction and improvements of symptoms and function in Chinese patients with symptomatic obstructive hypertrophic ...
Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian’an Wang, Yunqi Shi, Daoquan Peng, Ping Yang, Wei Ma, Fang Wang, Wei Jin, Xiang Cheng, Yu-Mao Chen, Yue Zhong, Yu Chen Barrett, Jing Zheng, Shuyang Zhang   +16 more
doaj   +1 more source

MAVACAMTEN NO TRATAMENTO DA CARDIOMIOPATIA HIPERTRÓFICA

RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218, 2023
Introdução: A cardiomiopatia hipertrófica (CMH) é uma das doenças cardíacas genéticas mais comuns, afetando entre 0,16% e 0,29% da população adulta geral. É uma doença genética do miocárdio e caracteriza-se por acentuada hipertrofia miocárdica que não pode ser explicada pela carga pressórica ou pela presença de desarranjo miocitário.
Caique Pereira de Paiva, Ana Clara Godinho de Freitas, Carla Lana Germinari Souza, Felipe Tochihide Iamaguti, Genon Henrique Costa Pinto, Júlia Peruzzi Iamaguti, Marina Romaquela Rodrigues, Tagstan Ribeiro Moioli, Taís Barbosa Honorato, Carollayne Mendonça Rocha   +9 more
openaire   +1 more source

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Journal of Clinical Medicine, 2023
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by an increased left ventricular wall thickness in the absence of increased afterload conditions. In addition to diastolic dysfunction, obstruction of the left ventricular outflow tract is common in HCM and has an important influence on symptoms and outcome. Over the last five decades
Scholtz, Smita (PD Dr. med.), Rudolph, Volker (PD Dr. med.), Reil, Jan-Christian (Dr. med.)   +2 more
openaire   +3 more sources

New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine [PDF]

, 2023
The strategic fluorination of oxidatively vulnerable sites in bioactive compounds is a relatively recent, widely used approach allowing us to modulate the stability, bio-absorption, and overall efficiency of pharmaceutical drugs.
Dhawan, Gagan, Han, Jianlin, Mei, Haibo, Soloshonok, Vadym Anatolievch, Wang, Nana, Zhang, Wei   +5 more
core   +1 more source

Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic‐Cardiodynamic Modeling to Support Safety and Efficacy

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT In the phase 3 study SEQUOIA‐HCM (NCT05186818), aficamten, a next‐in‐class cardiac myosin inhibitor, was safe and efficacious in participants with obstructive hypertrophic cardiomyopathy (oHCM). Using pharmacokinetics/pharmacodynamics (PKPD) modeling, we quantified the relationship between aficamten exposure and cardiodynamic measures of ...
Justin D. Lutz, Russ Wada, Daniel L. Jacoby, Stephen B. Heitner, Stuart Kupfer, Polina German   +5 more
wiley   +1 more source

Prospects for remodeling the hypertrophic heart with myosin modulators

Frontiers in Cardiovascular Medicine, 2022
Hypertrophic cardiomyopathy (HCM) is a complex but relatively common genetic disease that usually arises from pathogenic variants that disrupt sarcomere function and lead to variable structural, hypertrophic, and fibrotic remodeling of the heart which ...
Lorenzo R. Sewanan, Yuichi J. Shimada
doaj   +1 more source

Clinical Evaluation of Drug–Drug Interactions With Aficamten

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive drug–drug interaction (DDI) evaluation of aficamten was achieved through two phase 1 studies in ...
Neha Maharao, Donghong Xu, Punag Divanji, Tyrell J. Simkins, Jianlin Li, Camelia Dumitrescu, Priyanka Solanki, Adrienne Griffith, Stephen B. Heitner, Stuart Kupfer, Polina German, Justin D. Lutz   +11 more
wiley   +1 more source

One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy

Frontiers in Cardiovascular Medicine
Mavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM).
Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Emily L. Chu, Emily E. Keamy-Minor, Ishan Dhananjay Paranjpe, Wilson L. Tang, Jack W. O’Sullivan, Jack W. O’Sullivan, Jack W. O’Sullivan, Yaanik B. Desai, Yaanik B. Desai, Michael B. Liu, Michael B. Liu, Elise Munsey, Kimberly Hecker, Isabella Cuenco, Beth Kao, Ellen Bacolor, Colleen Bonnett, Andrea Linder, Kathleen Lacar, Nancy Robles, Cindy Lamendola, Allysonne Smith, Joshua W. Knowles, Joshua W. Knowles, Joshua W. Knowles, Joshua W. Knowles, Marco V. Perez, Marco V. Perez, Marco V. Perez, Marco V. Perez, Masataka Kawana, Masataka Kawana, Masataka Kawana, Karim I. Sallam, Karim I. Sallam, Karim I. Sallam, Chad S. Weldy, Chad S. Weldy, Chad S. Weldy, Matthew T. Wheeler, Matthew T. Wheeler, Matthew T. Wheeler, Matthew T. Wheeler, Victoria N. Parikh, Victoria N. Parikh, Victoria N. Parikh, Victoria N. Parikh, Heidi Salisbury, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, the Stanford Center for Inherited Cardiovascular Disease, Karim I Sallam, Masataka Kawana, Chad S Weldy, Marco Perez, Joshua W Knowles, Jason Tso, Cindy Lamendola, Allysonne Smith, Nancy Robles, Colleen Bonnett, Ellen Bacolor, Kimberly Hecker, Isabella Cuenco, Beth Kao, Elise Munsey, Andrea Linder, Kathleen Lacar, Julia Platt, Chloe Reuter, Tia Moscarello, Ryan Murtha, Jennifer Kohler, Hannah Ison, Mitchel Pariani, Anusha Klinder, Priya Nair, Jennifer Marino, Andrea Linder, Ruchi Patel, Matthew T Wheeler, Euan A Ashley, Victoria N Parikh   +92 more
doaj   +1 more source